Search

Your search keyword '"Mesropian, Agavni"' showing total 11 results
Start Over Author "Mesropian, Agavni"
11 results on '"Mesropian, Agavni"'

1. Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC

Author

Piqué-Gili, Marta, Andreu-Oller, Carmen, Mesropian, Agavni, Esteban-Fabró, Roger, Bárcena-Varela, Marina, Ruiz de Galarreta, Marina, Montironi, Carla, Martinez-Quetglas, Iris, Cappuyns, Sarah, Peix, Judit, Keraite, Ieva, Gris-Oliver, Albert, Fernández-Martínez, Elisa, Mauro, Ezequiel, Torres-Martin, Miguel, Abril-Fornaguera, Jordi, Lindblad, Katherine E., Lambrechts, Diether, Dekervel, Jeroen, Thung, Swan N., Sia, Daniela, Lujambio, Amaia, Pinyol, Roser, and Llovet, Josep M.

Published
2024
Full Text
View/download PDF

2. TOP-507-YI Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Author

Cappuyns, Sarah, primary, Piqué-Gili, Marta, additional, Esteban-Fabró, Roger, additional, Philips, Gino, additional, Pinyol, Roser, additional, Gris-Oliver, Albert, additional, Vandecaveye, Vincent, additional, Abril-Fornaguera, Jordi, additional, Montironi, Carla, additional, Bassaganyas, Laia, additional, Peix, Judit, additional, Zeitlhoefler, Marcus, additional, Mesropian, Agavni, additional, Huguet-Pradell, Júlia, additional, Haber, Philipp, additional, Mohr, Raphael, additional, Meyer, Tim, additional, Reeves, Helen Louise, additional, Edeline, Julien, additional, Finkelmeier, Fabian, additional, Trojan, Jörg, additional, Galle, Peter R., additional, Foerster, Friedrich, additional, Minguez, Beatriz, additional, Montal, Robert, additional, Heikenwälder, Mathias, additional, Verslype, Chris, additional, Van Cutsem, Eric, additional, Lambrechts, Diether, additional, Villanueva, Augusto, additional, Dekervel, Jeroen, additional, and Llovet, Josep, additional

Published
2024
Full Text
View/download PDF

3. FRI-467 Efficacy of WNTinib, a novel selective therapeutic for CTNNB1 mutant tumors, in preclinical models of hepatoblastoma

Author

Balaseviciute, Ugne, primary, Abril-Fornaguera, Jordi, additional, Huguet-Pradell, Júlia, additional, Rialdi, Alex, additional, Fernández-Martínez, Elisa, additional, Gris-Oliver, Albert, additional, Mesropian, Agavni, additional, Ulukaya, Gulay, additional, Hasson, Dan, additional, Keraite, Ieva, additional, Pinyol, Roser, additional, Thung, Swan N., additional, Guccione, Ernesto, additional, and Llovet, Josep, additional

Published
2024
Full Text
View/download PDF

4. Supplementary Figure from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma

Author

Esteban-Fabró, Roger, primary, Willoughby, Catherine E., primary, Piqué-Gili, Marta, primary, Montironi, Carla, primary, Abril-Fornaguera, Jordi, primary, Peix, Judit, primary, Torrens, Laura, primary, Mesropian, Agavni, primary, Balaseviciute, Ugne, primary, Miró-Mur, Francesc, primary, Mazzaferro, Vincenzo, primary, Pinyol, Roser, primary, and Llovet, Josep M., primary

Published
2023
Full Text
View/download PDF

5. Data from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma

Author

Esteban-Fabró, Roger, primary, Willoughby, Catherine E., primary, Piqué-Gili, Marta, primary, Montironi, Carla, primary, Abril-Fornaguera, Jordi, primary, Peix, Judit, primary, Torrens, Laura, primary, Mesropian, Agavni, primary, Balaseviciute, Ugne, primary, Miró-Mur, Francesc, primary, Mazzaferro, Vincenzo, primary, Pinyol, Roser, primary, and Llovet, Josep M., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Data from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma

Author

Esteban-Fabró, Roger, primary, Willoughby, Catherine E., primary, Piqué-Gili, Marta, primary, Montironi, Carla, primary, Abril-Fornaguera, Jordi, primary, Peix, Judit, primary, Torrens, Laura, primary, Mesropian, Agavni, primary, Balaseviciute, Ugne, primary, Miró-Mur, Francesc, primary, Mazzaferro, Vincenzo, primary, Pinyol, Roser, primary, and Llovet, Josep M., primary

Published
2023
Full Text
View/download PDF

7. Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma

Author

Esteban-Fabró, Roger, primary, Willoughby, Catherine E., additional, Piqué-Gili, Marta, additional, Montironi, Carla, additional, Abril-Fornaguera, Jordi, additional, Peix, Judit, additional, Torrens, Laura, additional, Mesropian, Agavni, additional, Balaseviciute, Ugne, additional, Miró-Mur, Francesc, additional, Mazzaferro, Vincenzo, additional, Pinyol, Roser, additional, and Llovet, Josep M., additional

Published
2022
Full Text
View/download PDF

8. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

Author

Montironi, Carla, primary, Castet, Florian, additional, Haber, Philipp K, additional, Pinyol, Roser, additional, Torres-Martin, Miguel, additional, Torrens, Laura, additional, Mesropian, Agavni, additional, Wang, Huan, additional, Puigvehi, Marc, additional, Maeda, Miho, additional, Leow, Wei Qiang, additional, Harrod, Elizabeth, additional, Taik, Patricia, additional, Chinburen, Jigjidsuren, additional, Taivanbaatar, Erdenebileg, additional, Chinbold, Enkhbold, additional, Solé Arqués, Manel, additional, Donovan, Michael, additional, Thung, Swan, additional, Neely, Jaclyn, additional, Mazzaferro, Vincenzo, additional, Anderson, Jeffrey, additional, Roayaie, Sasan, additional, Schwartz, Myron, additional, Villanueva, Augusto, additional, Friedman, Scott L, additional, Uzilov, Andrew, additional, Sia, Daniela, additional, and Llovet, Josep M, additional

Published
2022
Full Text
View/download PDF

9. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.

Author

Montironi, Carla, Castet, Florian, Haber, Philipp K., Pinyol, Roser, Torres-Martin, Miguel, Torrens, Laura, Mesropian, Agavni, Huan Wang, Puigvehi, Marc, Maeda, Miho, Wei Qiang Leow, Harrod, Elizabeth, Taik, Patricia, Chinburen, Jigjidsuren, Taivanbaatar, Erdenebileg, Chinbold, Enkhbold, Arqués, Manel Solé, Donovan, Michael, Swan Thung, and Neely, Jaclyn

Subjects
GENE expression, TYPE I interferons, MOLECULAR biology, TUMOR-infiltrating immune cells, CIRCULATING tumor DNA
Published
2023
Full Text
View/download PDF

10. Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma

Author

Torrens, Laura, primary, Montironi, Carla, additional, Puigvehí, Marc, additional, Mesropian, Agavni, additional, Leslie, Jack, additional, Haber, Philipp K., additional, Maeda, Miho, additional, Balaseviciute, Ugne, additional, Willoughby, Catherine E., additional, Abril‐Fornaguera, Jordi, additional, Piqué‐Gili, Marta, additional, Torres‐Martín, Miguel, additional, Peix, Judit, additional, Geh, Daniel, additional, Ramon‐Gil, Erik, additional, Saberi, Behnam, additional, Friedman, Scott L., additional, Mann, Derek A., additional, Sia, Daniela, additional, and Llovet, Josep M., additional

Published
2021
Full Text
View/download PDF

11. Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Author

Cappuyns S, Piqué-Gili M, Esteban-Fabró R, Philips G, Balaseviciute U, Pinyol R, Gris-Oliver A, Vandecaveye V, Abril-Fornaguera J, Montironi C, Bassaganyas L, Peix J, Zeitlhoefler M, Mesropian A, Huguet-Pradell J, Haber PK, Figueiredo I, Ioannou G, Gonzalez-Kozlova E, D'Alessio A, Mohr R, Meyer T, Lachenmayer A, Marquardt JU, Reeves HL, Edeline J, Finkelmeier F, Trojan J, Galle PR, Foerster F, Mínguez B, Montal R, Gnjatic S, Pinato DJ, Heikenwalder M, Verslype C, Van Cutsem E, Lambrechts D, Villanueva A, Dekervel J, and Llovet JM

Abstract

Background & Aims: The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit versus resistance to atezo+bev., Methods: We harnessed the power of single-cell RNA sequencing in advanced HCC to derive gene expression signatures recapitulating 21 cell phenotypes. These signatures were applied to 422 RNA-sequencing samples of advanced HCC patients treated with atezo+bev (n=317) versus atezolizumab (n=47) or sorafenib (n=58) as comparators., Results: We unveiled two distinct patterns of response to atezo+bev. First, an immune-mediated response characterized by the combined presence of CD8+ T effector cells and pro-inflammatory CXCL10+ macrophages, representing an immune rich microenvironment. Second, a non-immune, angiogenesis-related response distinguishable by a reduced expression of the VEGF co-receptor neuropilin-1 (NRP1), a biomarker that specifically predicts improved OS upon atezo+bev vs sorafenib (p = 0.039). Primary resistance was associated with an enrichment of immunosuppressive myeloid populations, namely CD14+ monocytes and TREM2+ macrophages, and Notch pathway activation. Based on these mechanistic insights we define "Immune-competent" and "Angiogenesis-driven" molecular subgroups, each associated with a significantly longer OS with atezo+bev versus sorafenib (p of interaction = 0.027), and a "Resistant" subset., Conclusion: Our study unveils two distinct molecular subsets of clinical benefit to atezolizumab plus bevacizumab in advanced HCC ("Immune-competent" and "Angiogenesis-driven") as well as the main traits of primary resistance to this therapy, thus providing a molecular framework to stratify patients based on clinical outcome and guiding potential strategies to overcome resistance., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results